The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2009Small Molecule Inhibitors of Alpha-synuclein Assembly and Toxicity
Objective/Rationale:
We will test a novel drug candidate that blocks formation of the toxic aggregates of the protein alpha-synuclein, which are believed to cause Parkinson’s disease (PD). Our drug... -
Rapid Response Innovation Awards, 2009Glycine Uptake Inhibitors as Potential Enhancers of Dopaminergic Axon Regeneration
Objective/Rationale
An important goal in Parkinson’s disease therapy is to restore the loss of the dopaminergic innervation of the striatum. Cell culture data from our lab indicate that activation of... -
Rapid Response Innovation Awards, 2009Multi-site Coordinated Reset Stimulation of the Subthalamic Nucleus
Objective/Rationale:
Current deep brain stimulation (DBS) does not take advantage of the latest discoveries of Parkinson’s disease (PD) pathophysiology which may explain some of its limitations... -
Rapid Response Innovation Awards, 2009The Role of Casein Kinase 2 in the Modulation of Dopamine Signaling in Parkinson's Disease
Objective/Rationale:
Parkinson’s disease is caused by a selective loss of cells in the brain that produce the neurotransmitter dopamine. The major treatment for PD is Levodopa (L-Dopa) which gets... -
Target Validation, 2009The Transcription Factor Nrf2 as a Target to Reduce Neurodegeneration and Neuroinflammation in Parkinson's Disease
Objective/Rationale:
Dopaminergic neuron loss and exacerbated neuroinflammation are events tightly involved in PD pathology that may result from an inadequate response to toxic, oxidant or inflammatory... -
Target Validation, 2009Neuroprotection by PXDNL, a Novel Heme-containing Peroxidase
Objective/Rationale:
Dysfunction of mitochondria in nerve cells contributes to the neurodegeneration of PD. When cells are infected by the CMV virus, they become resistant to certain mitochondrial...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.